Global HOPE (Hematology-Oncology Pediatric Excellence)

Partnership objectives 

Global HOPE (Hematology-Oncology Pediatric Excellence) is a comprehensive initiative which will build long-term capacity to treat and dramatically improve the prognosis of thousands of children with cancer and blood disorders in southern and eastern Africa.

 

A patient high fives Dr. Alan Anderson after a check-up following treatment for kidney cancer.  Dr. Anderson is one of the pediatric oncologists from Texas Children’s Hospital who will help train the estimated 4,800 African healthcare professionals. A patient high fives Dr. Alan Anderson after a check-up following treatment for kidney cancer. Dr. Anderson is one of the pediatric oncologists from Texas Children’s Hospital who will help train the estimated 4,800 African healthcare professionals. Copyright Barcode Media

What are the health needs and challenges? 

In the United States, 80 percent of children with cancer survive. In sub-Saharan Africa, the overwhelming majority of pediatric patients do not survive. The mortality rate is estimated to be as high as 90 percent, meaning that thousands of children die from cancer across Africa each year. This is in large part due to an inadequate healthcare infrastructure and a significant lack of expert physicians and other healthcare workers trained to treat children with cancer. The most common types of childhood cancers are blood cancers, including leukemia and lymphoma. 

There are only five pediatric oncologists currently in the countries of Botswana, Malawi and Uganda combined, there are simply not enough expert doctors to treat all the children diagnosed with blood disorders and cancer. It is estimated that in these countries there are more than 11,000 new cases annually of pediatric cancer and 40,000 new cases of serious, life-threatening blood disorders such as sickle cell disease and hemophilia. Because of these staggering numbers, more healthcare providers with special expertise are urgently needed. Global HOPE will help build capacity in the region to diagnose and care for children with blood disorders and cancer, offering the potential for transformational change in survivorship for these children.

Description of partnership activities and how they address needs and challenges 

The Bristol-Myers Squibb Foundation is committing $50 million over five years to fund the training of healthcare providers as well as clinical infrastructure and operations. BIPAI will raise an additional $50 million for the initiative.

Global HOPE will partner with local Governments and Ministries of Health to build medical capacity to diagnose and treat pediatric blood disorders and cancer in Botswana, Malawi and Uganda. The initiative will also create significant clinical, educational and research capabilities. Doctors, nurses and ancillary professionals will be recruited from around the world to provide training to local healthcare professionals and to begin treating children with blood disorders and cancer immediately.

Botswana and Uganda will also serve as regional hubs for pediatric hematology-oncology.

Summary of impact and forward looking information

As public-private partnerships, the various governments will each play an important role in developing the pediatric hematology-oncology network, assisting with the training, technical assistance, logistics and resources to support Global HOPE.

The Global HOPE initiative will train an estimated 4,800 healthcare professionals from Botswana, Uganda, Malawi and other African countries, including doctors, nurses, social workers and other health care workers involved in the treatment, care and support continuum of high qualitypediatric hematology-oncology. The program estimates that over 5,000 children will receive care in the first five years.

The Global HOPE initiative will be modeled on the work of the Bristol-Myers Squibb Foundation, BIPAI and the Governments of Botswana, Uganda and Malawi, which created the largest pediatric HIV treatment network in the world, leveraging existing experience, infrastructure, and public/private partnerships created through the initiative. Since 2003, the Bristol-Myers Squibb Foundation and BIPAI have trained 52,000 healthcare professionals and currently provide care for nearly 300,000 children with HIV and their families in sub-Saharan Africa, lowering the mortality rate for these children to 1.2 percent.

Measurement of progress towards objectives

Estimated overall value of partnership:

  • $100 million (US)
  • The Bristol-Myers Squibb Foundation is committing $50 million over five years to fund the training of healthcare providers as well as clinical infrastructure and operations.
  • BIPAI will raise an additional $50 million for the initiative.

Estimated amount of people impacted:

  • 4,800 healthcare professionals from Botswana, Uganda, Malawi and other African countries, including doctors and nurses specializing in pediatric hematology-oncology and social workers.
  • 5,000 children will receive care in the first five years.

Partnership information

Company(ies) Bristol-Myers Squibb

Partner(s) Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI), Botswana Ministry of Health, Bristol-Myers Squibb Foundation, Malawi Ministry of Health, Texas Children's Hospital, Texas Children’s Cancer and Hematology Centers, Uganda Ministry of Health

Type of Partner(s) Academia / Hospitals, Government

Therapeutic Focus Non-Communicable Diseases, Women and Children's Health

Disease(s) Cancer, Childhood Cancers, Children's Health, Haemophilia, Hematology Disorders, Leukemia, Sickle Cell Anemia

Program Type(s) Availability of Treatment - Patient Safety & Medicines Quality, Health System Infrastructure - Development of Physical Infrastructure, Health System Infrastructure - Outreach & Medical Services, Health System Infrastructure - Training, Research & Development - Operations Research, Research & Development - Pediatric R&D

Region(s) Sub-Saharan Africa

Number of Countries 3

Country(ies) Botswana, Malawi, Uganda

Start Date 2017

More information BMS Global Hope Childhood cancer BMS Foundation

Anticipated completion date 2022

« Working with our partners and drawing on our expertise of building health, we will help make an important difference in the outcomes for children and create a blueprint for other countries to follow. »

Giovanni Caforio, M.D., chairman of the board of the Bristol-Myers Squibb Foundation and chief executive officer, Bristol-Myers Squibb Company.